Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.

Drilon A, Nagasubramanian R, Blake JF, Ku N, Tuch BB, Ebata K, Smith S, Lauriault V, Kolakowski GR, Brandhuber BJ, Larsen PD, Bouhana KS, Winski SL, Hamor R, Wu WI, Parker A, Morales TH, Sullivan FX, DeWolf WE, Wollenberg LA, Gordon PR, Douglas-Lindsay DN, Scaltriti M, Benayed R, Raj S, Hanusch B, Schram AM, Jonsson P, Berger MF, Hechtman JF, Taylor BS, Andrews S, Rothenberg SM, Hyman DM.

Cancer Discov. 2017 Sep;7(9):963-972. doi: 10.1158/2159-8290.CD-17-0507. Epub 2017 Jun 3.

2.

Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Bachegowda L, Morrone K, Winski SL, Mantzaris I, Bartenstein M, Ramachandra N, Giricz O, Sukrithan V, Nwankwo G, Shahnaz S, Bhagat T, Bhattacharyya S, Assal A, Shastri A, Gordon-Mitchell S, Pellagatti A, Boultwood J, Schinke C, Yu Y, Guha C, Rizzi J, Garrus J, Brown S, Wollenberg L, Hogeland G, Wright D, Munson M, Rodriguez M, Gross S, Chantry D, Zou Y, Platanias L, Burgess LE, Pradhan K, Steidl U, Verma A.

Cancer Res. 2016 Aug 15;76(16):4841-4849. doi: 10.1158/0008-5472.CAN-15-3062. Epub 2016 Jun 10.

3.

A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.

Garcia-Manero G, Khoury HJ, Jabbour E, Lancet J, Winski SL, Cable L, Rush S, Maloney L, Hogeland G, Ptaszynski M, Calvo MC, Bohannan Z, List A, Kantarjian H, Komrokji R.

Clin Cancer Res. 2015 Mar 1;21(5):985-94. doi: 10.1158/1078-0432.CCR-14-1765. Epub 2014 Dec 5.

4.

OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models.

Garton AJ, Crew AP, Franklin M, Cooke AR, Wynne GM, Castaldo L, Kahler J, Winski SL, Franks A, Brown EN, Bittner MA, Keily JF, Briner P, Hidden C, Srebernak MC, Pirrit C, O'Connor M, Chan A, Vulevic B, Henninger D, Hart K, Sennello R, Li AH, Zhang T, Richardson F, Emerson DL, Castelhano AL, Arnold LD, Gibson NW.

Cancer Res. 2006 Jan 15;66(2):1015-24.

5.

Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).

Mulvihill MJ, Kan JL, Beck P, Bittner M, Cesario C, Cooke A, Keane DM, Nigro AI, Nillson C, Smith V, Srebernak M, Sun FL, Vrkljan M, Winski SL, Castelhano AL, Emerson D, Gibson N.

Bioorg Med Chem Lett. 2005 Mar 15;15(6):1669-73.

PMID:
15745819
7.

Subcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells.

Winski SL, Koutalos Y, Bentley DL, Ross D.

Cancer Res. 2002 Mar 1;62(5):1420-4.

8.

Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches.

Winski SL, Faig M, Bianchet MA, Siegel D, Swann E, Fung K, Duncan MW, Moody CJ, Amzel LM, Ross D.

Biochemistry. 2001 Dec 18;40(50):15135-42.

PMID:
11735396
9.

Differential involvement of caspases in hydroquinone-induced apoptosis in human leukemic hl-60 and jurkat cells.

Inayat-Hussain SH, Winski SL, Ross D.

Toxicol Appl Pharmacol. 2001 Sep 1;175(2):95-103.

PMID:
11543641
10.

Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones.

Winski SL, Swann E, Hargreaves RH, Dehn DL, Butler J, Moody CJ, Ross D.

Biochem Pharmacol. 2001 Jun 15;61(12):1509-16.

PMID:
11377380
11.

Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1.

Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, Ross D.

Mol Pharmacol. 2001 Feb;59(2):263-8.

PMID:
11160862
12.

NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms.

Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D.

Chem Biol Interact. 2000 Dec 1;129(1-2):77-97. Review.

PMID:
11154736
13.

Effects of parenteral cysteine and glutathione feeding in a baboon model of severe prematurity.

Stabler SP, Morton RL, Winski SL, Allen RH, White CW.

Am J Clin Nutr. 2000 Dec;72(6):1548-57.

PMID:
11101485
14.

Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1.

Siegel D, McGuinness SM, Winski SL, Ross D.

Pharmacogenetics. 1999 Feb;9(1):113-21. Erratum in: Pharmacogenetics 1999 Jun;9(3):419.

PMID:
10208650
16.
17.

Sequence of toxic events in arsine-induced hemolysis in vitro: implications for the mechanism of toxicity in human erythrocytes.

Winski SL, Barber DS, Rael LT, Carter DE.

Fundam Appl Toxicol. 1997 Aug;38(2):123-8.

PMID:
9299185
18.

Interactions of rat red blood cell sulfhydryls with arsenate and arsenite.

Winski SL, Carter DE.

J Toxicol Environ Health. 1995 Nov;46(3):379-97.

PMID:
7473865

Supplemental Content

Loading ...
Support Center